The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Table 5

Trials comparing MOPP- and ABVD-based regimens for the treatment of advanced stage Hodgkin disease. Numbers in bold are statistically significant with 𝑃 values where significant. *Febrile neutropenia. Abbreviations: OS: overall survival; MOPP: mechlorethamine, vincristine, procarbazine, prednisolone; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; MOPP/ABV: mechlorethamine, vincristine, procarbazine, prednisolone, doxorubicin, bleomycin, and vinblastine.

Treatment regimen; (author/trial)	No. of Pts	Outcome; (%, measure, time)	OS (%)	Haem toxicity; (% grade III-IV)	Second malignancy (haem/total, %)
MOPP	198	54 (FFP 20 y)	48	—	<2/− (10 y)
(Longo 1986)
MOPP	43	36 (FFP 8 y)	64	—	—
MOPP/ABVD alternating	45	65	84	—	—
(Bonadonna 1986)		𝑃<.005	𝑃<.06
6–8 MOPP	123	50 (FFS 5 y)	66	Increased	—
MOPP/ABVD alternating ×12	123	61	73	—	—
6–8 ABVD	115	65	75	—	—
(Canellos 1992)
MOPP/ABVD alternating	211	67 (FFP 10 y)	74	—	—
MOPP/ABVD hybrid	204	69	72	—	—
(Viviani 1996)
MOPP/ABV hybrid	153	71 (FFS 5 y)	81	18*	—
MOPP/ABVD alternating	148	67	83	7	—
(Connors 1997)				𝑃=.0001
MOPP/ABV	419	66 (FFS 5 y)	81	75	3/7
ABVD	433	63	82	64	0.005/4
(Duggan 2003)				𝑃=.001	𝑃=.011